Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells

Journal of Immunology

Volumn 162, Issue 6, 1999, Pages 3574-3582

  Tanaka, Hiroshi ^a   Yoshizawa, Hirohisa ^a   Yamaguchi, Yoshifumi ^a   Ito, Kazuhisa ^a   Kagamu, Hiroshi ^a   Suzuki, Eiichi ^a   Gejyo, Fumitake ^a   Hamada, Hirofumi ^b   Arakawa, Masaaki ^a  

^a NIIGATA UNIVERSITY   (Japan)

^b CANCER INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DNA DETERMINATION; DRUG EFFICACY; DRUG POTENCY; FIBROSARCOMA; GENE TRANSFER; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; IMMUNOTHERAPY; LUNG METASTASIS; LYMPH NODE CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD80; CARCINOMA, LEWIS LUNG; CELL DIVISION; FEMALE; FIBROSARCOMA; GENE TRANSFER TECHNIQUES; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; INTERLEUKIN-2; L-SELECTIN; LYMPH NODES; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0033559132     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Rosenberg, S. A., and W. D. Terry. 1977. Passive immunotherapy of cancer in animals and man. Adv. Cancer Res. 25:323.
2. Smith, H. G., R. P. Harmel, M. G. Hanna, Jr., B. S. Zwilling, B. Zbar, and H. J. Rapp. 1977. Regression of established intradermal tumors and lymph node metastases in guinea pigs after systemic transfer of immune lymphoid cells. J. Natl. Cancer Inst. 58:1315.
3. Fernandez-Cruz, E., B. Halliburton, and J. D. Feldman. 1979. In vivo elimination by specific effector cells of an established syngeneic rat moloney virus-induced sarcoma. J. Immunol. 123:1772.
4. Cheever, M. A., P. D. Greenberg, and A. Fefer. 1984. Potential for specific cancer therapy with immune T lymphocytes. J. Biol. Response Mod. 3:113.
5. Shu, S., and S. A. Rosenberg. 1985. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells. J. Immunol. 135:2895.
6. Yoshizawa, H., K. Sakai, A.E. Chang, and S. Shu. 1991. Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy. Cell. Immunol. 134:473.
7. Yoshizawa, H., A. E. Chang, and S. Shu. 1991. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J. Immunol. 147:729.
8. Yoshizawa, H., K. Sakai, A. E. Chang, and S. Shu. 1992. Cellular interactions in effector generation and tumor regression mediated by anti-CD3/interleukin 2 activated tumor-draining lymph node cells. Cancer Res. 52:1129.
9. Mitsuma, S., H. Yoshizawa, K. Ito, H. Moriyama, M. Wakabayashi, T. Chou, M. Arakawa, and S. Shu. 1994. Adoptive immunotherapy mediated by anti-TCR/ IL-2-activated tumour-draining lymph node cells. Immunology 83:45.
10. Miyao, H., T. Chou, K. Ito, H. Moriyama, S. Mitsuma, M. Wakabayashi, H. Yoshizawa, and M. Arakawa. 1994. Treatment of advanced primary lung cancer associated with malignant pleural effusion by the combination of immunotherapy and chemotherapy. Oncology 51:87.
11. Ito, K., T. Chou, S. Mitsuma, H. Moriyama, M. Wakabayashi, A. Mizusawa, H. Miyao, H. Yoshizawa, T. Tsuchiya, T. Ebe, L. Yuejing, and M. Arakawa. 1993. A novel chemo-immunotherapy for advanced non-small cell lung cancer. J. Jpn. Soc. Cancer Ther. 29:36.
12. Rosenberg, S. A., B. S. Packard, P. M. Aebersold, D. Solomon, S. L. Topalian, S. T. Toy, P. Simon, M. T. Lotze, J. C. Yang, C. A. Seipp, et al. 1988. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report. N. Engl. J. Med. 319:1676.
13. Rosenberg, S. A., P. Spiess, and R. Lafreniere. 1986. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318.
14. Topalian, S. L., D. Solomon, F. P. Avis, A. E. Chang, D. L. Freerksen, W. M. Linehan, M. T. Lotze, C. N. Robertson, C. A. Seipp, P. Simon, et al. 1988. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J. Clin. Oncol. 6:839.
15. Chang, A. E., H. Yoshizawa, K. Sakai, M. J. Cameron, V. K. Sondak, and S. Shu. 1993. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. Cancer Res. 53:1043.
16. Chang, A. E., A. Aruga, M. J. Cameron, V. K. Sondak, D. P. Normolle, B. A. Fox, and S. Shu. 1997. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J. Clin. Oncol. 15:796.
17. Fearon, E. R., D. M. Pardoll, T. Itaya, P. Golumbek, H. I. Levitsky, J. W. Simons, H. Karasuyama, B. Vogelstein, and P. Frost. 1990. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397.
18. Tsai, S. C., B. Gansbacher, L. Tait, F. R. Miller, and G. H. Heppner. 1993. Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts. J. Natl. Cancer Inst. 85:546.
19. Ohe, Y., E. R. Podack, K. J. Olsen, Y. Miyahara, T. Ohira, K. Miura, K. Nishio, and N. Saijo. 1993. Combination effect of vaccination with IL2 and IL4 cDNA transfected cells on the induction of a therapeutic immune response against Lewis lung carcinoma cells. Int. J. Cancer 53:432.
20. Tepper, R. I., P. K. Pattengale, and P. Leder. 1989. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57:503.
21. Golumbek, P. T., A. J. Lazenby, H. I. Levitsky, L. M. Jaffee, H. Karasuyama, M. Baker, and D. M. Pardoll. 1991. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254:713.
22. Okada, M., M. Kitahara, S. Kishimoto, T. Matsuda, T. Hirano, and T. Kishimoto. 1988. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J. Immunol. 141:1543.
23. Porgador, A., E. Tzehoval, A. Katz, E. Vadai, M. Revel, M. Feldman, and L. Eisenbach. 1992. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res. 52:3679.
24. Gansbacher, B., R. Bannerji, B. Daniels, K. Zier, K. Cronin, and E. Gilboa. 1990. Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res. 50:7820.
25. Nishihara, K., S. Miyatake, T. Sakata, J. Yamashita, H. Kikuchi, Y. Kawade, Y. Zu, Y. Namba, M. Hanaoka, and Y. Watanabe. 1988. Augmentation of tumor targeting in a line of glioma-specific mouse cytotoxic T-lymphocytes by retroviral expression of mouse γ-interferon complementary DNA. Cancer Res. 48: 4730.
26. Watanabe, Y., K. Kuribayashi, S. Miyatake, K. Nishihara, E. Nakayama, T. Taniyama, and T. Sakata. 1989. Exogenous expression of mouse interferon-γ cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc. Natl. Acad. Sci. USA 86:9456.
27. + T cells against the wild-type tumor: correlation with antigen presentation capability. J. Exp. Med. 175:1423.
28. Porgador, A., R. Bannerji, Y. Watanabe, M. Feldman, E. Gilboa, and L. Eisenbach. 1993. Antimetastatic vaccination of tumor-bearing mice with two types of IFN-γ gene-inserted tumor cells. J. Immunol. 150:1458.
29. Asher, A. L., J. J. Mule, A. Kasid, N. P. Restifo, J. C. Salo, C. M. Reichert, G. Jaffe, B. Fendly, M. Kriegler, and S. A. Rosenberg. 1991. Murine tumor cells transduced with the gene for tumor necrosis factor-α: evidence for paracrine immune effects of tumor necrosis factor against tumors. J. Immunol. 146:3227.
30. Karp, S. E., A. Farber, J. C. Salo, P. Hwu, G. Jaffe, A. L. Asher, E. Shiloni, N. P. Restifo, J. J. Mule, and S. A. Rosenberg. 1993. Cytokine secretion by genetically modified poorly immunogenic murine fibrosarcoma: tumor inhibition by IL-2 but not tumor necrosis factor. J. Immunol. 150:896.
31. Vanhaesebroeck, B., M. Mareel, F. Van Roy, J. Grooten, and W. Fiers. 1991. Expression of the tumor necrosis factor gene in tumor cells correlates with reduced tumorigenicity and reduced invasiveness in vivo. Cancer Res. 51:2229.
32. Colombo, M. P., G. Ferrari, A. Stoppacciaro, M. Parenza, M. Rodolfo, F. Mavilio, and G. Parmiani. 1991. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J. Exp. Med. 173:889.
33. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90:3539.
34. Arca, M. J., J. C. Krauss, A. Aruga, M. J. Cameron, S. Shu, and A. E. Chang. 1996. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor. Cancer Gene Ther. 3:39.
35. Ohno, K., H. Yoshizawa, H. Tsukada, T. Takeda, Y. Yamaguchi, K. Ichikawa, Y. Maruyama, Y. Suzuki, E. Suzuki, and M. Arakawa. 1996. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells. J. Immunol. 156:3875.
36. Linsley, P. S., and J. A. Ledbetter. 1993. The role of the CD28 receptor during T cell responses to antigen. Annu. Rev. Immunol. 11:191.
37. Schwartz, R. H. 1992. Costimulalion of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71: 1065.
38. Hathcock, K. S., G. Laszlo, C. Pucillo, P. Linsley, and R. J. Hodes. 1994. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J. Exp. Med. 180:631.
39. + T cells by B7-transfected melanoma cells. Science 259:368.
40. Chen, L., S. Ashe, W. A. Brady, I. Hellstrom, K. E. Hellstrom, J. A. Ledbetter, P. McGowan, and P. S. Linsley. 1992. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093.
41. Chen, L., P. McGowan, S. Ashe, J. Johnston, Y. Li, I. Hellstrom, and K. E. Hellstrom 1994. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 179:523.
42. Baskar, S., Rosenberg S. Ostrand, N. Nabavi, L. M. Nadler, G. J. Freeman, and L. H. Glimcher. 1993. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. USA 90:5687.
43. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J. Immunol. 153:421.
44. Ramarathinam, L., M. Castle, Y. Wu, and Y. Liu. 1994. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J. Exp. Med. 179:1205.
45. Karasuyama, H., A. Kudo, and F. Melchers. 1990. The proteins encoded by the VpreB and λ5 pre-B cell-specific genes can associate with each other and with μ heavy chain. J. Exp. Med. 172:969.
46. Wexler, H. 1966. Accurate identification of experimental pulmonary metastases J. Natl. Cancer Inst. 36:641.
47. Restifo, N. P., F. Esquivel, A. L. Asher, H. Stotter, R. J. Barth, J. R. Bennink, J. J. Mule, J. W. Yewdell, and S. A. Rosenberg. 1991. Defective presentation of endogenous antigens by a murine sarcoma: implications for the failure of an anti-tumor immune response. J. Immunol. 147:1453.
48. + T cell activity. J. Immunol. 148:648.
49. + T cell function. Jpn. J. Cancer Res. 84:315.
50. +, T cells from mammary tumor-bearing mice have a down-regulated production of IFN-γ: role of phosphatidyl serine. J. Immunol. 160:2735.
51. Kagamu, H., J. E. Touhalisky, G. E. Plautz, J. C. Krauss, and S. Shu. 1996. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes. Cancer Res. 56:4338.
52. Kagamu, H., and S. Shu. 1998. Purification of L-selectin (low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes. J. Immunol. 160:3444.